



(51) International Patent Classification:

C07D 473/18 (2006.01) **A61P 35/00** (2006.01)
A61K 31/522 (2006.01) **A61P 37/08** (2006.01)
A61P 29/00 (2006.01) **A61P 11/06** (2006.01)
A61P 31/00 (2006.01)

(21) International Application Number:

PCT/EP2011/051830

(22) International Filing Date:

8 February 2011 (08.02.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/303,010 10 February 2010 (10.02.2010) US

(71) **Applicant** (for all designated States except US): **GLAXO-SMITHKLINE LLC** [US/US]; One Franklin Plaza, 200 North 16th Street, Philadelphia, Pennsylvania 19102 (US).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **GIBBON, Robert Hermann** [GB/GB]; GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 0DP (GB). **LUCAS, Amanda** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **HERMITAGE, Stephen Andrew** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).

(74) **Agent**: **PRIESTLEY, Ruth Elizabeth**; GlaxoSmithKline, Global Patents (CN9 25.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) **Title**: 6-AMINO-2-{ [(1S)-1-METHYLBUTYL] OXY}-9-[5-(1-PIPERIDINYL)-7,9-DIHYDRO-8H-PURIN-8-ONE] MALEATE



(I)

(57) **Abstract**: A compound which is 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one: Formula (I) in the form of a maleate salt, may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.